Ultrawist 300

The drug is widely used to enhance contrast during examination of the human body for pathological changes. Ultravist 300 contains iodine, which allows darkening of certain areas of organs. Due to this, it becomes quite easy to notice any pathological changes in it.

Indications Ultrawist 300

Ultravist 300 is actively used to enhance image contrast during examination of organs and systems of the human body. It is used during computed tomography and arteriography, as well as venography. This also includes intravenous and intra-arterial digital subtraction angiography. The main indications for the use of Ultravist 300 are precise examinations of all body cavities.

The solution is widely used due to its many advantages, especially when performing angiocardiography. It is used in urography, retrograde cholangiopancreatography, galactography and phlebography. When administered subarachnoidally, it is used for myelography.

This Ultravist 300 is not a medicinal product. Ultravist 300 is not able to cure any diseases or alleviate the general condition of a person. Ultravist 300 is used exclusively for the purpose of studying the body, due to its specific composition.

Release form

Ultravist 300 is available exclusively as an injection solution. Ultravist 300 is transparent and does not contain any foreign particles. The main component is iopromide. The auxiliary components are sodium calcium edetate, trometamol and hydrochloric acid. The drug has several forms of release, they differ in their volume.

Thus, Ultravist 300 is available in 10 ml and 50 ml. Ultravist 300 is in glass bottles. It is supplied in an original cardboard box. There are bottles with a different volume, namely: 20 ml, 30 ml and 100 ml. All of them are also in cardboard boxes. The doctor conducting the study decides which volume of the drug to choose. Everything depends on the purpose of the work and the part of the body being studied. There are no other forms of release. The drug is intended exclusively for a complete study of the body and should not be used for other purposes.

[ 1 ]

Pharmacodynamics

The main component of the product is iopromide. Its molecular weight is 791.12. This component is a non-ionized, low-smol substance. It is also called a triiodinated radiopaque agent. Its main effect is to increase the clarity of the image. This occurs due to the ability of the main component - iodine, which is part of the solution, to absorb X-rays. This is the pharmacodynamics of the main component, which plays one of the most important roles in conducting an X-ray study.

In addition to iopromide, the solution also contains auxiliary components. These include sodium calcium edetate, hydrochloric acid, tometamol and distilled water. Their main function is to provide auxiliary assistance. No other data on the pharmacodynamics of the drug were presented.

[ 2 ]

Pharmacokinetics

After intravascular administration, Ultravist 300 begins to distribute rapidly across the intercellular space. Its complete elimination period is only 3 minutes, and this is in the distribution phase. Protein binding at low concentrations is 0.9. Some errors of ±0.2% are possible. The solution is unable to penetrate the intact blood-brain barrier. Despite this, it still penetrates the placenta in small quantities. After administration, the maximum amount of the main component in the plasma is observed after 4 hours. The basis of pharmacokinetics is not only distribution, but also metabolism with elimination.

After the solution is administered even in small quantities, there is no need to worry about the manifestations of metabolites, none have been detected. As for excretion, in people with normal kidney function, this period is only 2 hours. In this case, the administered dose is of no importance. Glomerular filtration cannot be ruled out. Half an hour after administration, about 18% of the total dose is excreted by the kidneys, after 3 hours almost 60%, and after 24 hours almost the entire administered solution. In 3 days, the solution completely leaves the body.

It is worth noting that patients with the last stage of renal failure should use the contrast agent with caution. Ultravist 300 can be eliminated by means of dialysis. Impaired renal function does not affect the process of drug elimination in any way. After all, in three days only 1.5% of the administered dose will be eliminated with feces.

[ 3 ], [ 4 ], [ 5 ]

Dosing and administration

Before using the solution, it must be warmed up to room temperature. It is necessary to examine the bottle before using it. If its integrity has been compromised or strange particles are visible, the solution must not be used. A special automatic injector is used to administer the contrast agent. In no case should multiple punctures be made. This will prevent a small amount of microparticles from getting into the finished solution. For intravascular administration, the method of application and dose of Ultravist 300 is determined by the doctor.

The solution must be administered in a horizontal position. If the patient has severe renal or hepatic insufficiency, the administered amount of contrast agent should be minimal. When using the agent, special attention is paid to the kidneys. They must be monitored for 3 days after the study. The dose is selected in accordance with the person's body weight, characteristics and age. Usually it is 1.5 grams per kilogram of weight. It may be exceeded, up to 300-350 ml.

For intravenous digital subtraction angiography, 300 mg of the agent per milliliter is used. The solution is administered as a bolus into the cubital vein. The rate of administration should not exceed 8-12 ml/s. It is possible to increase the rate of administration, but not more than 10-20 ml/s. If the bolus administration is rapid, this will reduce the time of contact of the contrast component with the vein walls.

For computed tomography, Ultravist 300 must be administered as a bolus. This is done using a special automatic injector. Part of the dose is administered this way, the rest within 6 minutes. During computed tomography of the whole body, the dosage depends on the organ being examined. Computed tomography of the skull requires the administration of 1-2.5 ml/kg of body weight.

Intravenous urography requires the administration of the agent over 1-2 minutes. The younger the patient, the earlier the image should be taken. The first image is taken immediately 3 minutes after the administration of the contrast agent.

For myelography, Ultravist 300 is administered in a dose of up to 12.5 ml. This is the maximum dosage. It should not be significantly increased if only one use is planned. When administered into body cavities, the entire process must be controlled by fluoroscopy. The dosage depends entirely on the patient's body weight and age. For arthrography, 5-15 ml of contrast agent is prescribed. For ERCP and examination of other cavities, everything depends on the clinical problem that needs to be solved.

[ 11 ]

Use Ultrawist 300 during pregnancy

There have been no necessary studies regarding the use of the solution during pregnancy. After all, it is highly inadvisable to be exposed to X-rays during this period. Therefore, the use of Ultravist 300 solution during pregnancy is prohibited. It is always necessary to compare the possible positive effect with the risk of damage to the developing fetus. An X-ray examination that includes the use of a contrast agent, or its complete absence, always carries a risk for the baby.

Animal studies show somewhat different results. Thus, the danger of using iodine for diagnostic purposes is completely excluded. The component is not capable of causing a risk to pregnancy, as well as harming the developing embryo and fetus, and, finally, subsequent births. Despite this, the process must be fully controlled by a specialist.

The safety of using the product in infants who are breastfed has not been fully studied. There is no data on the penetration of the injection through breast milk into the child's body. Excretion is insignificant, so the risk to the baby is unlikely.

Contraindications

There are no special contraindications, but there are some features of using the product. Thus, it is used with caution in case of intolerance, especially if a person suffers from cardiovascular diseases. Special recommendations also concern dysfunction of the thyroid gland. The main contraindication for use is the patient's advanced age and serious condition.

With intravascular administration, there is a risk of kidney damage, so people with impaired kidney function should use the solution with caution. Contrast agents can cause nephrotoxicity. This condition is characterized by a transient impairment of kidney function. It can occur after using Ultravist 300. In extremely rare cases, it leads to the development of acute renal failure. Ultravist 300 is extremely dangerous for people with diabetes mellitus, as well as multiple myelomas.

In cardiovascular diseases, there is a risk of serious changes in the human body. This may be both hemodynamics and arrhythmia. Intravascular administration leads to pulmonary edema in patients suffering from cardiovascular diseases. In case of nervous system disorders, there is a risk of seizures. Ultravist 300 is used with special caution in autoimmune diseases.

[ 6 ], [ 7 ]

Side effects Ultrawist 300

Allergic reactions may not occur very often. Side effects of Ultravist 300 include: urticaria, rash and erythema. In rare cases, anaphylactic shock occurs, which may include fatal cases. Vascular edema and mucocutaneous syndrome are possible. From the endocrine system, changes in the functionality of the thyroid gland and thyrotoxic crisis may develop.

The nervous system may also be affected. Headaches are quite common, dizziness and anxiety are possible. In extremely rare cases, hypoesthesia, fear, excessive agitation and convulsions occur. Loss of consciousness, as well as ischemia, stroke and paralysis are possible.

In terms of the visual organs, blurred vision and visual impairment may be observed. Conjunctivitis or lacrimation occur extremely rarely. The hearing organs may also react negatively. The cardiovascular system responds with chest pain, heart failure, and myocardial infarction. Blood pressure surges are possible.

From the respiratory system, sneezing is possible, in rare cases rhinitis and swelling of the mucous membrane. The pharynx, tongue, larynx and face may be affected, often swelling occurs in these areas. Respiratory failure and respiratory arrest cannot be ruled out.

From the digestive system, nausea, vomiting and taste disturbances may develop. Less often, diarrhea, stomach pain and swelling of the salivary glands appear. From the urinary system, renal dysfunction is possible. Acute renal failure may develop.

In general, the body may react with a failure of heat exchange, chills, increased sweating. In rare cases, a change in body temperature and local pain are observed.

[ 8 ], [ 9 ], [ 10 ]

Overdose

During the studies on the safety of the contrast agent on animals, no risks were found. Including the possible development of acute intoxication. With intravascular administration, an overdose is possible. It manifests itself in the form of a violation of the fluid balance. Electrolyte disorders are possible. The development of complications from the cardiovascular system, as well as the lungs, is not excluded. It is quite possible to eliminate negative symptoms. For this, fluid levels and electrolytes are monitored. It is also necessary to monitor the functionality of the kidneys. The essence of the treatment is to maintain the functionality of vital organs and body systems. If a certain dose was administered by mistake, the loss of water should be compensated. This is done by means of infusion. The person is monitored for 3 days.

When the solution is administered under the membrane of the brain, the risk of developing neurological complications cannot be ruled out. In this case, the patient must be under medical supervision. In order to prevent the risk of a large amount of solution entering the ventricles of the brain, a complete aspiration of the contrast component is performed. If the dose was mistakenly exceeded, it is necessary to monitor the state of the central nervous system during the first 12 hours. An increasing increase in reflexes is possible. In more severe cases, hyperthermia, respiratory depression and stupor are observed.

[ 12 ], [ 13 ], [ 14 ]

Interactions with other drugs

It is not recommended to use Ultravist 300 together with biguanides. The development of accumulation of the latter, as well as lactic acidosis, is possible. To prevent this complication, it is necessary to stop using biguanides 2 days before an X-ray examination, which involves the use of a contrast agent. Biguanides can be resumed only after kidney function is restored. Ultravist 300 can interact with other drugs, but only with extreme caution.

Simultaneous use of Ultravist 300 together with drugs that regulate a person's nervous state may reduce the seizure threshold. Such drugs include any neuroleptics and antidepressants. This increases the risk of developing reactions caused by the contrast agent used. Patients using beta-blockers may be resistant to drugs that have a beta-agonist effect.

Patients using a contrast agent together with interleukin B may experience delayed reactions. These include fever, rawness, and flu-like symptoms. For several days after using the contrast agent, you should stop taking thyroid-stimulating isotopes. They can reduce the effectiveness of diagnosing and eliminating thyroid disease.

[ 15 ], [ 16 ]

Storage conditions

The contrast agent must be stored in a special way. Ultravist 300 should not be open for a long time. In fact, the storage conditions require full compliance with the temperature regime. But if the substance has already been opened, then this does not matter. Thus, the temperature regime should not go beyond 30 degrees Celsius. It is desirable that the drug be kept out of the reach of children. It cannot be used in its pure form, it is administered exclusively by means of special devices into the organ that requires examination. Its entry into the gastrointestinal tract during oral use can lead to severe poisoning.

One clinical use of the drug may be limited due to its short period of use. In some cases, the presence of additional components in the contrast agent may lead to a delayed effect of the agent. The clinical use of these substances may be limited due to the short half-life of the contrast agent. This significantly limits the shelf life, even if all the basic rules are followed.

[ 17 ], [ 18 ]

Shelf life

Ultravist 300 is stored in a place protected from light. On average, the shelf life of the contrast agent is 3 years. During this period, it is necessary to follow all the main recommendations. It is advisable not to go beyond the permissible temperature range, which is 30 degrees. Children should not be allowed near the drug under any circumstances.

Throughout the entire expiration date, it is necessary to pay attention to the external data of the product. Ultravist 300 has a transparent consistency and does not contain any particles. Sediment is completely excluded. If this appears, it is prohibited to use the contrast agent. Before use, it is necessary to carefully inspect Ultravist 300.

The storage area should not contain moisture, direct sunlight and high temperatures. This will allow you to preserve all the beneficial properties of the product and use it for the specified time. There are no other special instructions regarding storage periods.

[ 19 ]